Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study
Authors:
- Nikolay N. MurashkinNMNikolay N. Murashkin
- Eduard T. AmbarchianEAEduard T. Ambarchian
- Roman V. EpishevRERoman V. Epishev
- Alexander I. MaterikinAMAlexander I. Materikin
- Leonid A. OpryatinLOLeonid A. Opryatin
- Roman A. IvanovRIRoman A. Ivanov
- Daria S. KukolevaDKDaria S. Kukoleva
- Marina Y. PomazanovaMPMarina Y. Pomazanova
- Daria G. KuptsovaDKDaria G. Kuptsova
- Yana V. KozyrYKYana V. Kozyr
- Andrey L. BakulevABAndrey L. Bakulev
Open Access
- 27 December 2020
- journal article
- research article
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 19 (6) , 531-537
Abstract
Background. The study of psoriasis biological therapy aspects in children has certain topicality due to the small number and disunity of individual observations and the lack of special registers for pediatric patients.Objective. Our aim was to study ustekinumab efficacy and safety in children with plaque (PP), erythrodermic (EP) and palmoplanar (PPP) forms of psoriasis.Methods. The analysis of ustekinumab efficacy and safety has been carrying out for 1 year. The evaluation of therapy efficacy was based on definition of improvement of PASI scores (PASI 75, PASI 90 and PASI 100) on the 16th, 28th, 40th and 52nd weeks of follow-up and children's dermatology life quality index (CDLQI). Ustekinumab therapy safety analysis was based on registration and evaluation of adverse effects. Results. The study included 67 children with PP, EP and PPP aged 12 to 18 years. PP group results: the PASI 75 response at the 52nd week of therapy was observed in 35 children (100%), PASI 90 — in 33 (94%), PASI 100 — in 30 (86%). EP group results: 10 patients (56%) have reached PASI 75 on the 16th week, while none of patients have improved to PASI 90 and PASI 100 scores. The PASI 75 response at the 52nd week of therapy was observed in 18 children (100%), PASI 90 — in 17 (94%), PASI 100 — in 7 (39%). Only 1 patient (7%) with PPP has showed the score decrease to PASI 75 on the 16th week. Adverse effects were reported in 2 patients.Conclusion. Ustekinumab is the effective and safe treatment for moderate and severe forms of PP and EP in children, and it can also be considered as one of the alternative methods for PPP treatment in pediatrics.Keywords
This publication has 25 references indexed in Scilit:
- Diagnosis and Treatment of Pediatric Psoriasis: Current and FutureAmerican Journal of Clinical Dermatology, 2013
- Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinicThe Journal of Dermatology, 2011
- Discovery and mechanism of ustekinumabmAbs, 2011
- Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)Journal of Dermatological Science, 2011
- The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical useBritish Journal of Dermatology, 2010
- Childhood psoriasis: a study of 137 cases from central ChinaWorld Journal of Pediatrics, 2010
- Incidence of psoriasis in children: A population-based studyJournal of the American Academy of Dermatology, 2010
- Epidemiology and comorbidity of psoriasis in childrenBritish Journal of Dermatology, 2009
- A review of acitretin, a systemic retinoid for the treatment of psoriasisExpert Opinion on Pharmacotherapy, 2005
- Psoriasis assessment tools in clinical trialsAnnals of the Rheumatic Diseases, 2005